How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment
Description:
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Sponsor:
Memorial Sloan Kettering Cancer Center
Contacts:
Thomas Kaley, MDkaleyt@mskcc.org
212-639-5122
Brandon Imber, MDimberb@mskcc.org
631-212-6346
Government Study Link:
NCT07223034 - Click here to see study onClinicalTrials.gov
68Ga-PSMA
Isotope(s):
Target(s):
- PSMA
Ligand: Small Molecules
Isotope(s):
Target(s):
- PSMA
